Health Boards
Fri-27-01-2017, 14:05 PM
Harder in Australia, Jim. I really am flummoxed by Belinda's claim that it was easy to get treatment here, especially as she had an anaphylactic reaction with one treatment. As you can read, it is compulsory to go through at least six months of hell to qualify, and Cosentyx got pulled from the list last October. No thanks. It is much easier self-medicating and being a guinea pig than dealing with these clowns.
<To qualify for PBS authority approval the following conditions must be met.
The patient:
is an adult with severe active psoriatic arthritis
and the patient has not received any PBS subsidised treatment
with adalimumab, certolizumab pegol, etanercept, and/or
golimumab, infliximab, secukinumab or ustekinumab in this
treatment cycle
has failed to achieve an adequate response following a
minimum of 3 months treatment with:
Methotrexate, at a dose of at least 20 mg/week
and
Sulfasalazine, at a dose of at least 2 g/day
or
Leflunomide, at a dose up to 20 mg/day
Provide details on contraindications or intolerance to any of the
prior therapies including the degree of toxicity.
Intolerance must be of a severity to necessitate permanent
treatment withdrawal.
Contraindication or toxicity and grade
Methotrexate:
Sulfasalazine:
Leflunomide:
The patient can demonstrate failure to achieve an adequate
response to current treatment by:
an elevated ESR greater than 25 mm/hr
and/or
an elevated CRP greater than 15 mg/L
and
an active joint count of at least 20 active (swollen and
tender) joints
or
at least 4 major active joints: elbow, wrist, knee, ankle,
shoulder and/or hip.
Note: Where a patient has at least 4 active major joints and less
than 20 total active joints at baseline, assessment of the major
joints only will be used for all continuing applications.>
<To qualify for PBS authority approval the following conditions must be met.
The patient:
is an adult with severe active psoriatic arthritis
and the patient has not received any PBS subsidised treatment
with adalimumab, certolizumab pegol, etanercept, and/or
golimumab, infliximab, secukinumab or ustekinumab in this
treatment cycle
has failed to achieve an adequate response following a
minimum of 3 months treatment with:
Methotrexate, at a dose of at least 20 mg/week
and
Sulfasalazine, at a dose of at least 2 g/day
or
Leflunomide, at a dose up to 20 mg/day
Provide details on contraindications or intolerance to any of the
prior therapies including the degree of toxicity.
Intolerance must be of a severity to necessitate permanent
treatment withdrawal.
Contraindication or toxicity and grade
Methotrexate:
Sulfasalazine:
Leflunomide:
The patient can demonstrate failure to achieve an adequate
response to current treatment by:
an elevated ESR greater than 25 mm/hr
and/or
an elevated CRP greater than 15 mg/L
and
an active joint count of at least 20 active (swollen and
tender) joints
or
at least 4 major active joints: elbow, wrist, knee, ankle,
shoulder and/or hip.
Note: Where a patient has at least 4 active major joints and less
than 20 total active joints at baseline, assessment of the major
joints only will be used for all continuing applications.>